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Just as non-lipidologists were becoming reconciled
to the complexities of networks of ceramide metab-
olism and the diverse roles of ceramide in cell regu-
lation and membrane structure, a new study reveals
a new layer of regulation of ceramide through the
actions of a ceramide binding/transfer protein.
As a bioactive molecule, ceramide has been implicated
in the regulation of cell growth, apoptosis, lifespan,
insulin resistance, vesicular trafficking, and a multitude
of specific cell actions and responses. In turn, aberrant
metabolism of ceramide has been associated with
inflammation, tumorigenesis, diabetes, and neurode-
generative disorders [1–4]. The regulation of ceramide
levels is now appreciated to be attributable to multiple
metabolic pathways (Figure 1) that either serve to gen-
erate ceramide or attenuate its levels. In fact, metabol-
ically, ceramide functions as a hub for sphingolipid
metabolism, having roles in regulating the formation of
important sphingolipids such as sphingomyelin (SM),
acylceramide, glucosylceramide, galactosylceramide,
and other complex glycosphingolipids. These gly-
cosphingolipids all have their own critical functions in
membrane rafts, receptor function, membrane con-
ductance, cell–cell interactions, and internalization of
pathogens [5–9]. From a signaling point of view,
ceramide also serves as the precursor to an ever-
increasing array of bioactive sphingolipids, including
sphingosine, sphingosine 1-phosphate and ceramide
1-phosphate [10]. Deciphering the regulation of
ceramide metabolism has therefore emerged as a
major goal in understanding the many functions and
properties of this lipid and its related sphingolipids. A
new study published recently in Nature [11] has now
revealed insights into ceramide metabolism by identi-
fying a protein, CERT, that is involved in SM biosyn-
thesis and acts as a ceramide transfer protein.
Previous efforts to understand sphingolipid metabo-
lism have been complicated by the immense difficul-
ties in working with these mostly hydrophobic
enzymes, in their purification, and in generating mole-
cular tools (cloned genes, knock-out models, RNAi,
antibodies) that would allow a more definitive investi-
gation of their properties, regulation and function. A
few enzymes of sphingolipid metabolism have been
approached by classical biochemical purification, for
example acid sphingomyelinase, neutral and acid
ceramidases, sphingosine kinase, and glucosylce-
ramide synthase. The predominant majority of the
remaining enzymes, however, has only recently yielded
to genetic approaches, mostly from studies in Saccha-
romyces cerevisiae, including ceramide synthase, alka-
line ceramidases, sphingosine kinases, sphingosine
phosphate phosphatases and sphingosine phosphate
lyase. It now appears that all enzymes of sphingolipid
metabolism in S. cerevisiae have been identified mole-
cularly, and this has assisted the identification of many
mammalian counterparts [12].
The most notable and vexing exception to this rapid
progress has been the recalcitrant mammalian SM syn-
thase. This is a particularly exciting enzyme(s) that not
only regulates SM formation, but also regulates — in a
reciprocal manner — the levels of ceramide and diacyl-
glycerol (DAG), two critical bioactive lipids. Indeed, bio-
chemical studies suggest the existence of at least two
SM synthases — one in the Golgi compartment that
appears to be critical for formation of bulk SM (destined
for the outer leaflet of the plasma membrane) and a dis-
tinct SM synthase (probably in close proximity to the
plasma membrane) that may be more concerned with
the regulation of DAG and ceramide (and there may
possibly be a third nuclear enzyme) [6,13,14]. Remark-
ably, very recently, considerable progress has been
made in the identification of this class of enzymes. A
bacterial SM synthase was first purified and identified
in Pseudomonas aeruginosa [15], and a novel class of
at least two animal SM synthases was subsequently
discovered [16]. In particular, two of these animal SM
synthases appear to be consistently expressed in
mammals and, in agreement with the biochemical
studies reported earlier, one localizes to the Golgi and
one to both the Golgi and the plasma membrane.
Nishijima’s group used a mammalian genetic
approach to identify enzymes of sphingolipid metab-
olism, including SM synthase, using mutagenized
Chinese hamster ovary cells [17]. Hanada et al. used
the toxin lysenin, which induces cell lysis as a direct
result of its binding to SM present at the outer leaflet
of the plasma membrane, to identify temperature-sen-
sitive mutants deficient in SM and therefore resistant
to the cytotoxic effects of lysenin. One mutant pre-
sented a defect in SM biosynthesis but not in SM syn-
thase itself [17]. In their more recent work [11], they
have traced this molecular defect to a gene encoding
CERT, a soluble cytosolic protein previously identified
as a binding partner for Goodpasture antigen (a
protein marker of Goodpasture disease, a disorder of
kidney and lung inflammation).
Where does CERT fit in the scheme of ceramide
metabolism? An inherent danger in presenting ceramide
metabolism and function in an oversimplified scheme
(Figure 1) is the potential to mislead the non-lipidologist
that these are directly connected pathways. Unlike gly-
colytic pathways which are mostly diffusion-limited,
ceramide, one of the most hydrophobic lipids in the cell,
is usually ‘trapped’ in the particular membrane where it
is formed. Thus, one has to consider compartmentaliza-
tion of ceramide function. The recent identification of
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distinct and compartment-specific ceramidases (lyso-
somal, Golgi, ER, mitochondria, and plasma membrane)
[18] provides compelling proof for organelle-specific
metabolism of ceramide. Ceramide’s hydrophobic prop-
erties raise another specific question of how it is trans-
ferred from the ER, its site of synthesis, to the Golgi, the
primary site of SM and glycosphingolipid synthesis.
Hanada et al. [11] show that CERT significantly con-
tributes to SM biosynthesis and go on to provide con-
vincing evidence that this protein functions as a
ceramide transfer protein in vitro, selectively extracting
ceramide from phospholipid vesicles and transferring it
to ceramide-poor vesicles. Cell-free studies show
clearly that wild-type (but not mutant) CERT reconsti-
tutes SM synthesis in the mutant cells. CERT harbors a
phosphatidylinositol (PI) binding domain with selectiv-
ity toward PI-4 phosphate (PI4P), a lipid known to be
enriched in Golgi membranes and thus speculated to
function as the delivery address for CERT-carried
ceramide (Figure 2). Interestingly, CERT does not affect
the Golgi-localized synthesis of glucosylceramide, and
the ceramide substrate for this reaction appears to
reach the Golgi by vesicular traffic. Thus, CERT
emerges as a specific regulator of SM biosynthesis,
providing more evidence for the compartmentalized
metabolism and function of ceramide.
These studies raise a number of interesting ques-
tions regarding the regulation of CERT and whether
CERT is an important regulator of SM levels and func-
tion. As SM is a key component of lipid rafts, its levels
may be important for raft function. A potential role for
CERT in regulating SM function in rafts is supported
by the previously reported phenotype of CERT mutant
cells, as these cells have lower levels of detergent-
resistant membrane-associated cholesterol, which
could lead to raft dysfunction [19].
Previous results show that the absence of CERT
does not cause appreciable accumulation of ceramide
in resting cells, suggesting some form of feedback inhi-
bition [19]. But what would happen under conditions of
stimulation of de novo synthesis of ceramide, such as
in response to cytokines or chemotherapeutic agents;
would this result in greater accumulation of ceramide
(as SM synthesis can no longer act as a ‘sink’ to absorb
the additional ceramide)? Interestingly, examining the
primary sequence of CERT reveals multiple candidates
for caspase cleavage (e.g., DEDD, VEDD, and VGGD),
and although these are very tentative, they do raise the
possibility of regulating CERT during apoptosis. 
In terms of its mechanistic action, CERT must be
able to deliver ceramide to the Golgi and then ‘return’
to the ER. How are the ‘on’ and ‘off’ steps regulated?
When ceramide reaches the cytosolic side of the Golgi,
does it simply flip to the lumenal side, the site of SM
synthesis? What is the role of ATP in SM synthesis?
These multiple steps in CERT function offer a variety of
possibilities for regulation of function, for example the
regulation of levels of PI4P and its localization.
CERT joins the ranks of other lipid transfer proteins
such as phosphatidylinositol transfer protein (PITP) α
and β, the latter with specificity for the transfer of SM
and possible roles in regulating synthesis and/or deliv-
ery of SM at the plasma membrane [20]. CERT also
emerges as a ceramide ‘binding’ protein, adding to the
known ceramide-metabolizing enzymes and ceramide-
regulated effectors (Figure 1). Yet, the identification of
specific ceramide-binding ‘domains’ has eluded inves-
tigators. This is not an easy goal as ceramide exhibits
high hydrophobicity and is present in cells at relatively
significant levels (around 0.1–1 mol % total lipids); affini-
ties of ceramide-binding proteins must therefore be
fairly small. Interestingly, the identification of binding
domains for DAG (which has similar hydrophobicity as
ceramide and is present at similar cellular levels) was
achieved primarily by defining domains that bind to
phorbol ester, which mimics the action of DAG, under-
scoring the difficulties in biochemical identification of
ceramide-binding domains.
Thus, ceramide biology now brings together metab-
olism, signaling, and transfer between subcellular
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Figure 1. Ceramide-interacting proteins. 
Proteins that interact directly with
ceramide include two major groups. The
first comprises the many enzymes of
ceramide metabolism (blue; see text for
examples). The second group (green) is
composed of signaling proteins that are
regulated, at least in part, by their interac-
tions with ceramide, including protein
phosphatases 1 and 2A (PP1 and PP2A),
protein kinase  Cζ (PKCζ), Raf-1 and the
kinase suppressor of Ras (KSR), and
cathepsin D [18]. Hanada et al. [11] have
disclosed a third type of ceramide-
binding protein (pink) which is repre-
sented by CERT. SMS, sphingomyelin
synthase; GluCerS, glucosylceramide
synthase; GalCerS, galactosylceramide
synthase; CerK, ceramide kinase; Acyl-
CerS, 1-O-Acylceramide synthase;
CDase, ceramidase; GalCer, galactosyl-
ceramide; GluCer, glucosylceramide; PC,
phosphatidylcholine; Cer-P, ceramide-1-
phosphate; AcylCer, acylceramide.
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compartments. Future molecular studies of ceramide-
interacting proteins promise further exciting discover-
ies and insights.
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Figure 2. Ceramide metabolism and unresolved questions. 
Ceramide (squares) is synthesized de novo in the ER by
ceramide synthase. Once formed, ceramide reaches the Golgi
apparatus (mainly cis and medial) [5,13] where it is converted
into more complex sphingolipids, such as sphingomyelin (trian-
gles) and glucosylceramide by SMS and GCS, respectively.
Ceramide destined for conversion to glucosylceramide appears
to reach the Golgi by vesicular transport, and the ceramide in
the cytosolic leaflet of the Golgi membrane becomes accessible
to the catalytic site of GCS. On the other hand, ceramide des-
tined for the formation of SM reaches the Golgi by both an ATP-
dependent, vesicle-independent transport pathway mediated by
CERT and a minor ATP-independent transport pathway, possi-
bly vesicular. CERT is proposed to extract ceramide from the
cytosolic leaflet of the ER and to deliver it to the cytosolic leaflet
of the Golgi membrane through its interaction with PI4P (pen-
tagons), which is particularly enriched in Golgi membranes. The
mechanisms that regulate the release of CERT from the Golgi
are yet to be elucidated. In order to access the catalytic site of
SMS, which is oriented toward the lumen of the Golgi, ceramide
must flip to the opposite leaflet through an as yet uncharacter-
ized mechanism. Also the molecular mechanism that deter-
mines specificity of CERT toward SMS and not GCS needs to be
further elucidated. A possible scenario could include the exis-
tence of PI4P-enriched microdomains in close proximity to
SMS. Alternatively, a specific interaction of CERT with a cytoso-
lic domain of SMS or with an as yet unknown SMS-interacting
factor could target CERT in close proximity to SMS. The newly
synthesized SM is then transported to the outer leaflet of the
plasma membrane from the lumenal leaflet of the Golgi mainly
by a vesicle-mediated mechanism. An additional Golgi-to-
plasma membrane transport mechanism may involve PITPβ,
which has been shown to bind and transport phosphatidylinos-
itol, phosphatidylcholine and SM and to translocate from the
cytosol to the Golgi [20]. In this case, the SM from the lumenal
membrane of the Golgi must flip to the cytosolic membrane in
order to be available for interaction with the PITPβ.
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